Researcher looks to break the chain of a lethal inheritance; FDA suspends early study of Vertex diabetes therapy

Anna Greka has become a champion for patients with rare diseases, blurring the sharp lines that often lie between the lab and the real world. ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ 

Sponsored by   Hundreds of families share a lethal inheritance. This kidney researcher hopes to break the chain By Isabella Cueto Evan Kafka for STAT Anna Greka has become a champion for patients with rare diseases, blurring the sharp lines that often lie between the lab and the real world. Read More STAT+: FDA suspends early study of Vertex stem-cell therapy for type 1 diabetes By Adam Feuerstein Bill Sikes/AP The agency's decision to place a clinical hold on Vertex’s diabetes therapy called VX-880 was a “surprise,” the company told STAT. Read More Listen: 'Birthing while Black' is an American crisis. Communities demand justice By Nicholas St. Fleur Keisha Okafor for STAT For the fourth episode of "Color Code," we look at how communities are fighting to fix America's Black maternal mortality crisis. Read More Sponsor content by Primary Care for America What if America built a health care system that is focused on keeping people healthy? What if everyone had a primary care team? What if America deliberately pursued health and well-being? The health care system in this country often prioritizes profits and margins over patient care and outcomes. It's time to have a serious talk about how to make real change. It’s time to change the conversation and prioritize primary care. Primary Care for America is doing just that. See the possibilities. Paxlovid's failure as a preventative measure raises questions, but doctors still back it as a therapeutic By Matthew Herper Pfizer Still useful for those at risk of severe Covid symptoms, Paxlovid falls short where monoclonals had succeeded. Read More STAT+: Meet the lawmakers and lobbyists who want to bring health tech into the home By Mohana Ravindranath Adobe The future of telehealth and other home health care depends on what types of virtual and in-person care at home Medicare will eventually decide to cover. Read More The brain 'learns' to have seizures more efficiently and frequently over time, mouse study shows By Jonathan Wosen Courtesy Juliet Knowles and Michelle Monje-Deisseroth Scientists found that mice and rats that suffered from seizures developed changes in the wiring of their brains that advanced the disease. Read More STAT+: Despite biotech slump, veterans of SVB and KKR launch investment firm By Allison DeAngelis Courtesy Katherine Smith Enavate, started by alumni of SVB and KKR, will encourage treatment of specific diseases. Read More Opinion: Substituting genetic ancestry for race in research? Not so fast By Anna C. F. Lewis Adobe Turning to genetic ancestry to understand biological differences between groups can perpetuate the same problems as relying on race. Read More Monday, May 2, 2022       1 Exchange Pl, Suite 201, Boston, MA 02109 ©2022, All Rights Reserved. I no longer wish to receive STAT emails Update Email Preferences | Contact Us | View In Browser